Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    YXT.com

    MCap

    USD127m

    Last close

    USD23.43

    ▲ 20.23 (632.19%)

    Northern Data Group

    MCap

    EUR486m

    Last close

    EUR7.56

    ▲ 2.33 (44.59%)

    Bodycote

    MCap

    GBP1,572m

    Last close

    GBP9.23

    ▲ 173.00 (23.07%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Immix Biopharma – equity proposition

Immix Biopharma – equity proposition

Immix Biopharma — 2 videos in collection

More on this equity

Immix Biopharma is a clinical-stage, US-based, Nasdaq-listed biotechnology company. Its lead asset, NXC-201, is a BCMA-targeting CAR-T cell therapy being developed for relapsed or refractory amyloid light chain amyloidosis (r/r ALA). This is a rare and serious disease in which abnormal plasma cells produce misfolded light chains that can build up in organs, most often the heart, kidneys and liver, leading to progressive organ damage. Immix is now focused on advancing NXC-201 through the US-based NEXICART-2 trial. Patient enrolment was completed in March 2026, with the next update expected in Q326.

We highlight the key points of Immix’s investment story.

  1. NXC-201 addresses a rare disease with a clear unmet medical need.
  2. Clinical data to date have been highly encouraging.
  3. The safety profile could offer a meaningful differentiation point.
  4. Immix is well funded through key upcoming milestones.

For further details, please refer to our latest research on Immix Biopharma.

< Previous
Next >

You may also be interested in these:

Healthcare

Immix Biopharma - executive interview
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.